JPMorgan raised the firm’s price target on Xencor (XNCR) to $14 from $13 and keeps a Neutral rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Trump plans to fire FDA commissioner Marty Makary, WSJ reports
- Xencor reports Q1 EPS ($1.71), consensus (75c)
- Buy Rating on Xencor as TL1A Franchise Data and Upcoming Phase IIb Catalyst Support Upside Potential
- Xencor Highlights TL1A Autoimmune Portfolio and IBD Strategy
- Xencor to host webcast to discuss XmAb942, XmAb412 data presentations